PS02.245: GLUTATHIONE S-TRANSFERASE PI 1 (GSTP1) IS ONE OF VALUABLE PREDICTORS RELATED TO POOR PROGNOSIS AND RESISTANCE TO CHEMOTHERAPY IN ESOPHAGEAL CANCER. (14th September 2018)

• Record Type: Journal Article
• Authors: Ogino, Shinpei; Konishi, Hirotaka; Matsubara, Daiki; Shoda, Katsutoshi; Arita, Tomohiro; Kosuga, Toshiyuki; Shiozaki, Atsushi; Okamoto, Kazuma; Otsuji, Eigo
• Is Part Of: Diseases of the esophagus. Volume 31(2018)Supplement 1
• Page Start: 191
• Page End: 192
• Publication Date: 2018-09-14
• Subjects: GSTP1 -- Esophageal cancer -- chemothrapy -- prognosis; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1093/dote/doy089.PS02.245
• Languages: English
• ISSNs: 1120-8694

Abstract

Abstract: Background: Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies worldwide, however, there is no useful marker for diagnosis and treatment. Glutathione S-transferase Pi 1 (GSTP1) is a member of GST family, a phase-II metabolic enzyme, and has reported as a predictor of malignancy and sensitivity to anti-cancer drugs in some cancers. In this study, we investigated the association of GSTP1 expression with malignancy and resistance to chemotherapy in ESCC patients. Methods: The ability of proliferation and sensitivity to anti-cancer drugs regarding GSTP1 expression were examined in ESCC cell lines, KYSE170 and TE13. Proliferation assay and apoptosis assay using fluorescent activated cell sorting (FACS) were performed. In addition, immunohistochemistry assays of tissue samples were performed in 75 ESCC patients without neoadjuvant chemotherapy and 71 patients with neoadjuvant chemotherapy. Results: The proliferation of GSTP1 knockdown cells were significantly decreased compared to that of control cells in KYSE170 and TE13. Similarly, the frequency of early apoptosis in GSTP1 knockdown cells were higher than that of control cells. Survival rate of GSTP1 knockdown cells treated with cisplatin was lower than that of control cells in chemoresistance assays. Moreover, the frequency of early apoptosis in GSTP1 knockdown cells treated with cisplatin were markedly higher than that of control cells. In immunohistochemistry assay of ESCC patients without neoadjuvant chemotherapy, high GSTP1 expression was an independent predictor of a poor prognosis ( P = 0.029). Regarding immunohistochemistry assay of tissue samples with neoadjuvant chemotherapy, GSTP1 expression significantly associated with downstaging of clinical stage ( P = 0.042). Conclusion: GSTP1 related to the prognosis and resistance to chemotherapy in ESCC patients. However, accurate assessment of resected specimen with chemotherapy was difficult because tumor cells sensitive to chemotherapy were already absent. Further analysis using samples without chemotherapy such as biopsy samples would be more appropriate for the assessment of the sensitivity to chemotherapy. Disclosure: All authors have declared no conflicts of interest.